With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Therapy with Skyrizi is 600mg given by infusion at weeks zero, four and eight, followed by a 360mg subcutaneous shot given at week 12 and every eight weeks thereafter. The FDA is also reviewing a ...

and AbbVie’s Skyrizi (risankizumab). Both drugs brought in $132m and $11bn respectively, however, both currently rely on an initial intravenous infusion. J&J’s competition does have the edge ...

induction therapy to eliminate the need for in-clinic IV infusions required for Skyrizi and Omvoh. The ASTRO trial, whose full results will be revealed at ECCO 2025, has already demonstrated ...

“Some of the ones that we give in the infusion center are Rituxan and Skyrizi. We give that one very often for rheumatoid arthritis” While there is no cure for rheumatoid arthritis, staying active and ...

Both drugs brought in $132m and $11bn respectively, however, both currently rely on an initial intravenous infusion. J&J’s competition does have the edge in certain IBD indications, however, with both ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...